Brazil market clears Y-mAbs cancer drug for children
Danyelza will be marketed by partner firm Adium Pharma.
by albert rønning-andersson, translated by daniel pedersen
Doctors in Brazil will be able to add another tool to their toolbox when treating children with refractory or relapsed neuroblastoma – which is the most common type of childhood cancer outside the brain.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Y-mabs suffers 16-0 defeat at FDA vote
For subscribers
